Suppr超能文献

基于绩效的风险分担安排:最新国际综述。

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

机构信息

Pharmaceutical Outcomes Research and Policy Program, University of Washington, 1959 NE Pacific St., Box 357630, Seattle, WA, 98195-7630, USA.

出版信息

Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z.

Abstract

Enthusiasm for performance-based risk-sharing arrangements (PBRSAs) continues but at variable pace across countries. Our objective was to identify and characterize publicly available cases and related trends for these arrangements. We performed a review of PBRSAs from 1993 to 2016 using the University of Washington PBRSA Database. Arrangements were categorized according to a previously published taxonomy. Macro-level trends were identified related to the timing of adoption, countries involved, types of arrangements, and disease areas. Our search yielded 437 arrangements. Among these, 183 (41.9%) were categorized as currently active, while 58.1% have expired. Five main types of arrangements have been identified, namely coverage with evidence development (149 cases, 34.1%), performance-linked reimbursement (104 cases, 23.8%), conditional treatment continuation (78 cases, 17.8%), financial or utilization (71 cases, 16.2%), and hybrid schemes with multiple components (35 cases, 8.0%). The pace of adoption varies across countries but has renewed an upward trend after a lull in 2012/2013. Conditions in the USA may be changing toward a more favorable environment of PBRSAs. Interest in PBRSAs remains high, suggesting they are a viable coverage and reimbursement mechanism for a wide range of medical products.

摘要

对基于绩效的风险分担安排(PBRSAs)的热情在各国之间持续存在,但速度不一。我们的目的是确定和描述这些安排的公开案例和相关趋势。我们使用华盛顿大学 PBRSAs 数据库,对 1993 年至 2016 年的 PBRSAs 进行了回顾。根据之前发表的分类法对安排进行了分类。确定了与采用时间、涉及国家、安排类型和疾病领域相关的宏观趋势。我们的搜索结果为 437 个安排。其中,183 个(41.9%)被归类为当前活跃,而 58.1%已经过期。已经确定了五种主要类型的安排,即有证据开发的覆盖范围(149 例,34.1%)、与绩效挂钩的报销(104 例,23.8%)、有条件的治疗延续(78 例,17.8%)、财务或利用(71 例,16.2%)和具有多个组件的混合方案(35 例,8.0%)。采用的步伐在各国之间有所不同,但在 2012/2013 年的停顿之后,又重新呈现上升趋势。美国的情况可能正在朝着有利于 PBRSAs 的环境转变。对 PBRSAs 的兴趣仍然很高,这表明它们是广泛的医疗产品的可行的覆盖范围和报销机制。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验